OrganiGram Holdings Inc.

Most Recent

  • OrganiGram advertisement
    Cannabis

    Why OrganiGram (OGI) Stock Is So Expensive Right Now

    By Ambrish Shah
  • organigram stock forecast
    Cannabis

    Organigram's Stock Forecast: Should You Buy the Penny Pot Stock?

    By Mohit Oberoi, CFA
  • uploads///organigram analysts revise
    Cannabis

    OrganiGram Stock Falls after Disappointing Q3 Earnings

    Today, OrganiGram Holdings (NASDAQ:OGI) reported its third-quarter earnings. As expected, the results were disappointing.

    By Rajiv Nanjapla
  • uploads///marijuana montana
    Cannabis

    Marijuana Legalization Proceeds in Montana amid COVID-19

    New Approach Montana resumed its marijuana legalization campaign in May. The group submitted plenty of signatures and qualified for the November ballot.

    By Sushree Mohanty
  • uploads///Organigram
    Cannabis

    Haywood Capital Markets Reduced OrganiGram’s Target Price

    OrganiGram (NASDAQ:OGI) stock is trading higher before its third-quarter earnings. The stock closed with a gain of 3.9% at $1.58 on Wednesday.

    By Sushree Mohanty
  • uploads///OGI_
    Cannabis

    What to Expect from OrganiGram’s Q3 Earnings

    OrganiGram will likely report its third-quarter earnings before the market opens on July 21. Overall, there isn’t much hope.

    By Rajiv Nanjapla
  • uploads///curaleaf__
    Cannabis

    Aphria Stock Rose More than 8% after Stifel’s Upgrade

    Aphria (NYSE:APHA) received a bullish call from Stifel. On Monday, Stifel upgraded the stock from a “hold” to a “buy” rating.

    By Rajiv Nanjapla
  • uploads///aphria and organigram comparing
    Cannabis

    Is Aphria or OrganiGram a Better Buy for Investors?

    Analysts expect Aphria to report revenues of $631.8 million in the next four quarters. Management will focus on the medical and recreational sectors.

    By Rajiv Nanjapla
  • uploads///nebraska marijuana
    Cannabis

    Marijuana Legalization Hopes Rise in Nebraska for 2020

    Marijuana legalization hopes never really ended in Nebraska. Signature gathering paused in the state amid the pandemic and the lockdown.

    By Sushree Mohanty
  • uploads///arizona marijuana ballott
    Cannabis

    Arizona’s Marijuana Campaign Qualifies for November Ballot

    Marijuana campaigns in most US states faced challenges gathering enough signatures amid the pandemic. However, Arizona got plenty of signatures.

    By Sushree Mohanty
  • uploads///kushco struggles
    Cannabis

    KushCo Holdings Reported Lower Q3 Results, Stock Rose 10%

    KushCo Holdings’ third-quarter net revenue was $22.3 million, which was much lower than analysts’ estimate of $31.1 million.

    By Sushree Mohanty
  • uploads///kushco earnings
    Cannabis

    What to Expect from KushCo Holdings’ Q3 Earnings

    KushCo Holdings will likely report its third-quarter results on Wednesday. The company will have an earnings call before the market opens.

    By Sushree Mohanty
  • uploads///innovative industrial properties cash
    Cannabis

    Innovative Industrial Properties Raises More Cash amid Crisis

    On June 30, Innovative Industrial Properties announced its decision to raise additional capital of $225 million through a public offering of its common stock.

    By Sushree Mohanty
  • uploads///aurora cannabis new cco
    Cannabis

    Aurora Cannabis Appoints New Chief Commercial Officer

    As the demand for Cannabis 2.0 products continues to rise, Aurora Cannabis announced the appointment of Miguel Martin as its new chief commercial officer.

    By Rajiv Nanjapla
  • uploads///organigram delay
    Cannabis

    OrganiGram Lays Off 220 Employees, Delays Q3 Earnings

    To survive amid the current COVID-19 crisis, OrganiGram (NASDAQ:OGI) announced restructuring changes including a 25% cut in its workforce.

    By Sushree Mohanty
  • uploads///Acb_
    Cannabis

    Why Did Raymond James Downgrade OrganiGram?

    On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.

    By Rajiv Nanjapla
  • uploads///cronos group raymond james bullish
    Cannabis

    Why Is Raymond James Bullish on Cronos Group?

    Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”

    By Rajiv Nanjapla
  • uploads///marijuana fed reserve bank
    Cannabis

    Marijuana Legalization Catches Federal Reserve Bank’s Attention

    The spotlight is on marijuana legalization as the demand keeps surging. More states have stepped up to legalize either recreational or medical cannabis.

    By Sushree Mohanty
  • uploads///us marijuana legal
    Cannabis

    Canopy Growth CEO Expects US to Legalize Cannabis by 2022

    Amid the growing support for cannabis legalization, Canopy Growth (NYSE:CGC) CEO David Klein expects the federal government to legalize marijuana by 2022.

    By Rajiv Nanjapla
  • uploads///cannabis top  stocks
    Cannabis

    Top 2 Cannabis Stocks to Buy, Interest in the Sector Reignites

    After underperforming the broader equity markets in the first quarter, the cannabis sector has been showing a strong recovery in the second quarter.

    By Rajiv Nanjapla
  • uploads///Curaleaf
    Cannabis

    Curaleaf Expands Select Brand Medical Products in Connecticut

    On Monday, Curaleaf Holdings announced that it will expand its Select brand products in Connecticut. The products will be available at medical dispensaries.

    By Rajiv Nanjapla
  • uploads///hexo wall street expectations
    Cannabis

    Wall Street’s Expectations after Hexo’s Q3 Earnings

    Hexo (TSE:HEXO) reported better-than-expected results for the third quarter of fiscal 2020 last week. The company repeatedly disappointed investors in 2019.

    By Sushree Mohanty
  • uploads///OrganiGram_
    Cannabis

    OrganiGram Stock Rose Due to New International Agreement

    On Wednesday, OrganiGram Holdings (NASDAQ:OGI) announced that its subsidiary OrganiGram signed a supply agreement with Canndoc.

    By Rajiv Nanjapla
  • uploads///curaleaf
    Consumer

    Why Does Paradigm Capital Favor OrganiGram Holdings?

    Paradigm Capital analyst Corey Hammill is bullish on OrganiGram. He rated the stock as a “buy” with a target price of 4.00 Canadian dollars.

    By Rajiv Nanjapla
  • uploads///aurora cannabis aphria cantor fitzgerald
    Cannabis

    Aurora and Aphria Look Attractive for Cantor Fitzgerald

    Since Aurora Cannabis reported its third-quarter earnings on May 14, its stock has more than doubled. The company is still trading 42.4% down YTD.

    By Rajiv Nanjapla
  • uploads///OGI_
    Cannabis

    Why Is Raymond James Bullish on OrganiGram?

    Rahul Sarugaser of Raymond James is upbeat on OrganiGram Holdings (NASDAQ:OGI). The company amended its credit facility with the Bank of Montreal.

    By Rajiv Nanjapla
  • uploads///OGI_
    Cannabis

    Why OrganiGram Stock Rose More than 11% Yesterday

    OrganiGram (NASDAQ:OGI) had good news for patients who use cannabis for medical purposes. The company expanded its medical cannabis offerings.

    By Rajiv Nanjapla
  • uploads///canopy growth buy q
    Cannabis

    Why Canopy Growth Is a ‘Buy’ before Its Earnings

    Despite the surge in May, Canopy Growth is still trading at a 54.3% discount from its 52-week high of $59.74. So, should you buy the stock?

    By Rajiv Nanjapla
  • uploads///Aurora Cannabis
    Cannabis

    Aurora Cannabis to Enter US CBD Market, Stock Rises over 30%

    On Wednesday, Aurora Cannabis (NYSE:ACB) announced that it has signed an agreement to acquire Reliva—a US-based CBD company.

    By Rajiv Nanjapla
  • uploads///aurora cannabis q results announce
    Cannabis

    Why Analysts Still Aren’t Convinced about Aurora Cannabis

    Since Aurora Cannabis reported its third-quarter earnings, Piper Sandler upgraded the stock from “underweight” to “neutral.” Analysts favor a “hold” rating.

    By Rajiv Nanjapla
  • uploads///aurora cannabis q results announce
    Cannabis

    Aurora Cannabis: Q3 Revenue Beat the Estimates

    Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.

    By Sushree Mohanty
  • uploads///GW Pharmaceuticals results
    Cannabis

    GW Pharmaceuticals Stock Rises on Higher Epidiolex Sales

    On Monday, GW Pharmaceuticals reported its first-quarter earnings. The company beat analysts’ revenue, EBITDA, and EPS expectations.

    By Rajiv Nanjapla
  • uploads///cronos group higher sales
    Cannabis

    Cronos Group’s Q1 Revenue Driven by Higher Marijuana Sales

    Cronos Group (NASDAQ:CRON) reported its results for the first quarter of fiscal 2020 on May 8. The revenue improved from the fourth quarter of fiscal 2019.

    By Sushree Mohanty
  • uploads///aphria stock fell
    Cannabis

    Why Did Aphria Stock Fall 7% on May 8?

    On May 8, Aphria’s (NYSE:APHA) management announced that it agreed to repurchase its convertible senior notes from some holders outside of Canada.

    By Rajiv Nanjapla
  • uploads///massachusetts cannabis aid
    Cannabis

    Massachusetts Wants to Help Cannabis Businesses amid COVID-19

    Massachusetts made medical cannabis essential amid the COVID-19 pandemic. However, recreational cannabis dispensaries had to shut down.

    By Sushree Mohanty
  • uploads///hexo molson coors
    Cannabis

    Will Hexo Rebound with Its Molson Coors CBD Deal?

    Hexo (TSE:HEXO) has been struggling for a while now and things aren’t looking good. The stock has lost close to 70.2% year-to-date.

    By Sushree Mohanty
  • uploads///marijuana mexico
    Cannabis

    Marijuana Legalization in Mexico Isn’t Likely in 2020

    Marijuana legalization in Mexico looks hazy this year. Mexico won’t see marijuana legalization before December 15—the end of the next legislative session.

    By Sushree Mohanty
  • uploads///Canopy Growth
    Cannabis

    Canopy Growth to Exit Africa, Close Another Canadian Facility

    Canopy Growth announced another set of global operational changes to optimize its production, improve efficiency, and align its supply with the demand.

    By Rajiv Nanjapla
  • uploads///aphria mixed reactions
    Cannabis

    Why Analysts Had Mixed Reactions to Aphria’s Q3 Earnings

    On April 14, Aphria (NYSE:APHA) reported its third-quarter earnings. For the quarter, the company reported revenues of 144.4 million Canadian dollars.

    By Rajiv Nanjapla
  • uploads///marijuana campaign missouri
    Cannabis

    COVID-19 Ends Marijuana Legalization Campaign in Missouri

    Marijuana legalization efforts started struggling in Missouri after the coronavirus pandemic hit. The campaign struggled to obtain the required signatures.

    By Sushree Mohanty
  • uploads///organigram stock weak results
    Cannabis

    Wall Street Is Bearish after OrganiGram’s Q2 Results

    OrganiGram’s second-quarter results didn’t meet the expectations. Many analysts downgraded the stock and cut the target price.

    By Sushree Mohanty
  • uploads///organigram second quarter results
    Cannabis

    OrganiGram Posted Its Q2 Earnings, Stock Fell 12%

    OrganiGram (NASDAQ:OGI) reported its results for the second quarter of fiscal 2020 on April 14 before the market opened. The results weren’t impressive.

    By Sushree Mohanty
  • uploads///aphria results
    Cannabis

    Aphria Reported Impressive Q3 Results, Beat Expectations

    On Tuesday, Aphria (NYSE:APHA) reported its third-quarter results. The company reported impressive third-quarter results and beat analysts’ expectations.

    By Rajiv Nanjapla
  • uploads///cannabis problem solution
    Cannabis

    Cannabis Faces Barriers in Washington and Michigan

    Washington has included cannabis on the list of essential items. However, the COVID-19 crisis has caused the state to make some strict changes.

    By Sushree Mohanty
  • uploads///organigram q results
    Cannabis

    OrganiGram: Analysts Aren’t Hopeful about Its Q2 Earnings

    OrganiGram will report its results for the second quarter of fiscal 2020 on April 14 before the market opens. Analysts aren’t hopeful about the results.

    By Sushree Mohanty
  • uploads///joe biden marijuana
    Cannabis

    Should Joe Biden Support Marijuana Legalization?

    Marijuana is gaining a lot of attention amid the coronavirus pandemic. Many people think that Joe Biden should support marijuana legalization.

    By Sushree Mohanty
  • uploads///kushco
    Cannabis

    KushCo Posted Disappointing Q2 Results, Stock Rose 8%

    KushCo’s second-quarter revenue was almost in line with analysts’ estimates. The company reported revenue of $30.14 million.

    By Sushree Mohanty
  • uploads///Aphria_
    Cannabis

    Will Aphria’s Q3 Earnings Lift the Cannabis Sector?

    Analysts expect Aphria to report revenue of 130.6 million Canadian dollars in the third quarter—growth of 77.5% YoY and a sequential increase of 8.3%.

    By Rajiv Nanjapla
  • uploads///organigram analysts revise
    Cannabis

    OrganiGram: Analysts Revise 2020 Estimates in April

    Analysts have lowered the revenue estimates for OrganiGram for fiscal 2020. Analysts expect the revenue to be around 127 million Canadian dollars.

    By Sushree Mohanty
  • uploads///marijuana survive covid
    Cannabis

    Will the Marijuana Industry Survive COVID-19?

    Despite increased sales, the marijuana industry’s struggles haven’t ended. Temporarily closing stores and laying off employees will take a toll.

    By Sushree Mohanty
  • uploads///OrganiGram
    Cannabis

    OrganiGram to Reduce Workforce by 45% Due to COVID-19

    OrganiGram has joined the list of cannabis companies, like Canopy Growth and Aurora Cannabis, that will reduce their workforce.

    By Rajiv Nanjapla
  • uploads///cronos group revision
    Cannabis

    Cronos Group: Analysts Revise Estimates in April

    Cronos Group disappointed analysts and investors with its results for the fourth quarter of fiscal 2019. The company missed analysts’ revenue estimates.

    By Sushree Mohanty
  • uploads///Canopy Growth
    Cannabis

    Canopy Growth’s Vaporizer Device Gets Health Canada Approval

    On April 3, Canopy Growth (NYSE:CGC)(TSE:WEED) announced that Health Canada issued a medical device license for Volcano Medic 2—its vaporizing device.

    By Rajiv Nanjapla
  • uploads///organigram and aphria compare
    Cannabis

    Comparing OrganiGram and Aphria’s Valuation Multiples

    So far this year, OrganiGram Holdings (NASDAQ:OGI) and Aphria (NYSE:APHA) have lost 11.0% and 36.7% of their stock price.

    By Rajiv Nanjapla
  • uploads///hexo stock fell earnings
    Cannabis

    Hexo Stock Tanks after Reporting Its Q2 Earnings

    Today, Hexo (TSE:HEXO) reported its earnings results for the second quarter of fiscal 2020. The company reported revenues of 17.0 million Canadian dollars.

    By Rajiv Nanjapla
  • uploads///CWEB_
    Cannabis

    Analysts’ Recommendations after Charlotte’s Web’s Q4 Earnings

    Charlotte’s Web Holdings reported its fourth-quarter earnings on March 24. For the quarter, the company missed analysts’ revenue and EBITDA estimates.

    By Rajiv Nanjapla
  • uploads///curaleaf target price
    Cannabis

    Analysts Cut Curaleaf’s Target Price after Its Q4 Earnings

    Since Curaleaf reported its fourth-quarter earnings on March 24, Alliance Global Partners and Canaccord Genuity have lowered their target prices.

    By Rajiv Nanjapla
  • uploads///marijuana essential
    Cannabis

    COVID-19 Pandemic Made Marijuana an Essential Item

    Amid the coronavirus pandemic, marijuana has become an essential item in many US states. As a result, there was a surge in cannabis demand.

    By Sushree Mohanty
  • uploads///aphria analysts bullish
    Cannabis

    Wall Street Has a Bullish Outlook for Aphria in March

    Aphria (NYSE:APHA) is one of the cannabis stocks that investors and analysts still like. They’re confident that the stock will outperform.

    By Sushree Mohanty
  • uploads///charlottes web earnings
    Cannabis

    Charlotte’s Web Stock Rose after Its Q4 Earnings

    Today, Charlotte’s Web Holdings (TSE:CWEB)(OTCMKTS:CWBHF) reported its fourth-quarter earnings. For the quarter, the company reported revenues of $22.8 million.

    By Rajiv Nanjapla
  • uploads///marijuana
    Cannabis

    New York Senator Wants to Delay Marijuana Legalization

    New York Senator Liz Krueger thinks that the state needs to deal with the coronavirus pandemic. The state doesn’t need to rush marijuana legalization.

    By Sushree Mohanty
  • uploads///organigram health canada license
    Cannabis

    OrganiGram Receives Expansion License from Health Canada

    On Monday, OrganiGram Holdings (NASDAQ:OGI) announced that it received a license from Health Canada to expand its Phase 5.

    By Rajiv Nanjapla
  • uploads///Aphria_OGI
    Cannabis

    Why Did Bank of America Upgrade Aphria and OrganiGram?

    On March 19, Bank of America upgraded Aphria (NYSE:APHA) and OrganiGram Holdings (NASDAQ:OGI) due to the increased demand for cannabis.

    By Rajiv Nanjapla
  • uploads///curaleaf upcoming results
    Cannabis

    Analysts Recommend a ‘Buy’ for Curaleaf before Its Q4 Earnings

    As of Thursday, nine analysts covered Curaleaf. Among the analysts, eight recommend a “buy,” while one recommends a “hold.”

    By Rajiv Nanjapla
  • uploads///tilray target price cut
    Cannabis

    Tilray’s Q4 Earnings Force Analysts to Cut Its Target Price

    Tilray (NASDAQ:TLRY) reported dismal results for the fourth quarter of fiscal 2019 on Tuesday. The losses widened in the fourth quarter.

    By Sushree Mohanty
  • uploads///Green Growth
    Cannabis

    What Do Analysts Recommend for Green Growth Brands?

    After Green Growth Brands reported its earnings, Eight Capital downgraded the stock from “buy” to “sell.” Currently, three analysts follow the company.

    By Rajiv Nanjapla
  • uploads///organigram analysts recommendations
    Cannabis

    OrganiGram: What Do Analysts Recommend Right Now?

    As of February 28, OrganiGram Holdings (NASDAQ:OGI) was trading at 2.98 Canadian dollars—a fall of 6.6% since the beginning of this year.

    By Rajiv Nanjapla
  • uploads///IIPR
    Cannabis

    What Can You Expect from IIPR’s Q4 Earnings?

    IIPR will report its results for the fourth quarter of 2019 today after the market closes. Analysts expect the company to post revenue and EPS growth.

    By Rajiv Nanjapla
  • uploads///Marijuana
    Cannabis

    Minnesota’s Second Attempt at Marijuana Legalization

    Marijuana is legal for medicinal purposes in Minnesota. Soon, lawmakers will present another bill for marijuana legalization in the state.

    By Sushree Mohanty
  • uploads///mariju
    Cannabis

    Marijuana Vape Products Expected in Alberta Stores

    AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

    By Rajiv Nanjapla
  • uploads///Marijuana
    Cannabis

    Singapore Government Asks Netflix to Block Marijuana Shows

    Some countries still have very strict marijuana laws. Recently, Singapore’s government asked Netflix to block all marijuana shows and films in the country.

    By Sushree Mohanty
  • uploads///Marijuana
    Cannabis

    Pete Buttigieg’s Bold Stance on Marijuana Legalization

    Pete Buttigieg took a bold stance to legalize marijuana. He said that he has a “Plan B” for marijuana legalization, which involves using Air Force One.

    By Sushree Mohanty
  • uploads///marijuana
    Cannabis

    Bernie Sanders Vows to Legalize Marijuana in 50 States if Elected

    Recently, at a rally, Bernie Sanders announced that he will legalize marijuana in all 50 states in the US if he wins the presidential election.

    By Sushree Mohanty
  • uploads///Cannabis
    Cannabis

    Congress Takes Steps in Favor of Cannabis Research

    Congress held a hearing on January 15 to discuss the six cannabis-related reform proposals. Lawmakers discussed the problems that the US faces.

    By Sushree Mohanty
  • uploads///Trump
    Cannabis

    What Does President Trump Think about Marijuana?

    President Trump hasn’t directly supported or opposed marijuana. In the past, he said that marijuana makes people “lose IQ points.”

    By Sushree Mohanty
  • uploads///Aphria
    Cannabis

    Is Aphria a Good Cannabis Pick for 2020?

    Aphria has successfully strengthened its position not only in Canada but also in international markets. The company reported impressive second-quarter results.

    By Sushree Mohanty
  • uploads///CL_
    Cannabis

    Cresco Labs Stock Rose after Securing $100 Million Loan

    On Thursday, Cresco Labs announced that it signed an agreement for a senior secured term loan for an initial aggregate principal amount of $100 million.

    By Rajiv Nanjapla
  • uploads///Aurora Cannabis
    Cannabis

    Is There Hope for Aurora Cannabis in 2020?

    Aurora Cannabis is one of the big names in the cannabis space. The company had a hard time in 2019 due to lower revenues and profitability.

    By Sushree Mohanty
  • uploads///CL_
    Cannabis

    Is Cresco Labs a Good Bet in January?

    Analysts expect Cresco Labs to report revenues of $45.3 million in the fourth quarter to take the total revenue for 2019 to $131.9 million.

    By Rajiv Nanjapla
  • uploads///Aphria
    Analyst Price Target

    Why Jefferies Went Bearish on Aphria and Bullish on OGI

    On Monday, Jefferies reduced the target price for Aphria stock to 10.3 Canadian dollars from 11 Canadian dollars. Why is Jefferies bearish?

    By Sushree Mohanty
  • uploads///OrganiGram_
    Cannabis

    OrganiGram: Analysts’ Ratings and Target Prices after Q1 Earnings

    As of Monday, OrganiGram Holdings (OGI) was trading at 4.21 Canadian dollars—a rise of 49.8% since reporting its first-quarter earnings on January 14.

    By Rajiv Nanjapla
  • uploads///Cronos
    Cannabis

    Analysts’ Outlook for Cronos Group in January

    Jefferies reduced the target price for Cronos Group stock to $5.3 from $7.5. The stock’s average target price is set at 12.0 Canadian dollars.

    By Sushree Mohanty
  • uploads///Cannabis
    Cannabis

    Washington’s New Cannabis Bill Could Push Illegal Sales

    Washington state will be strict with its cannabis laws. Since the state legalized adult-use marijuana in 2012, the laws have been very straightforward.

    By Sushree Mohanty
  • uploads///Marijuana
    Cannabis

    New Hampshire Tries Different Strategy to Legalize Marijuana

    In New Hampshire, the state legislature thinks that the new bill has hope. The bill doesn’t support the commercialization of marijuana, which was the issue earlier.

    By Sushree Mohanty
  • uploads///Illinois
    Cannabis

    How’s the Illinois Marijuana Market Shaping Up?

    Illinois is the 11th US state to legalize recreational marijuana. The demand for adult-use marijuana is high in the state. So far, the launch has been successful.

    By Sushree Mohanty
  • uploads///APHA_
    Cannabis

    Comparing APHA and OGI’s Valuation Multiples

    As of Wednesday, Aphria (NYSE:APHA) was trading at a forward EV-to-sales multiple of 2.38x. The valuation multiple increased despite the lower stock price.

    By Rajiv Nanjapla
  • uploads///cannabis
    Cannabis

    Cannabis Situation in Texas after Hemp Law Confusion

    Texas attempted to legalize hemp last year. However, there was a lot of confusion about whether the state legalized or decriminalized cannabis.

    By Sushree Mohanty
  • uploads///Organigram
    Cannabis

    OrganiGram Posts Incredible Q1 Results, Solid Outlook

    In the first quarter, OrganiGram beat analysts’ revenue estimates. The company has been an interesting pick in the cannabis space.

    By Sushree Mohanty
  • uploads///OGI_
    Cannabis

    Can OrganiGram Beat Analysts’ Expectations in Q1?

    OrganiGram Holdings will report its first-quarter earnings after the market closes today. We expect the company to miss analysts’ consensus estimates.

    By Rajiv Nanjapla
  • uploads///GW Pharmaceuticals
    Cannabis

    GW Pharmaceuticals Provides Preliminary Sales Update

    On January 12, GW Pharmaceuticals announced its preliminary unaudited product sales report for the fourth quarter and 2019.

    By Rajiv Nanjapla
  • uploads///KushCo_
    Cannabis

    What Do Analysts Recommend for KushCo Holdings?

    KushCo Holdings reported its Q1 earnings on January 8. KushCo reported revenue of $34.96 million, below analysts’ forecast of $41.5 million.

    By Rajiv Nanjapla
  • uploads///KushCo
    Cannabis

    Did KushCo Meet Analysts’ Expectations in Q1 2020?

    KushCo reported its fiscal 2020 first-quarter results yesterday. Analysts expected the company to post double-digit percent revenue growth in the quarter.

    By Sushree Mohanty
  • uploads///OGI_pic
    Cannabis

    OrganiGram’s First-Quarter Earnings: What to Expect

    Yesterday, OrganiGram stock was trading at 2.68 Canadian dollars, 23.4% lower than when the company reported its fourth-quarter earnings on November 25.

    By Rajiv Nanjapla
  • uploads///Organigram
    Cannabis

    Organigram Has Analysts Confident ahead of Q1 Earnings

    Organigram is set to report its fiscal 2020 first-quarter earnings on January 14. The company’s fiscal 2019 fourth-quarter results were stable.

    By Sushree Mohanty
  • uploads///Jan_
    Cannabis

    Why Cannabis Stocks Are Falling Today

    Weakness in cannabis stocks continued today, the fourth day of decline. The US equity market fell today due to the growing tension between the US and Iran.

    By Rajiv Nanjapla
  • uploads///can_
    Cannabis

    Cannabis Sector Marks Third Straight Day of Decline

    The downward momentum in cannabis stocks has continued today, marking the third straight day of decline for the cannabis sector.

    By Rajiv Nanjapla
  • uploads///Untitdddled
    Cannabis

    Here’s What Delta 9 Cannabis 2.0 Looks Like

    In a recent update, Delta 9 Cannabis Inc. (NINE.V) presented details about its cannabis 2.0 products and its sales in the initial phase. Delta 9 Cannabis recently launched new recreational products in its retail stores in Manitoba. Following that, the company released the sales updates to its investors. Cannabis 2.0 in Canada Health Canada allowed […]

    By Nivedha Elango
  • uploads///TerrAscend
    Cannabis

    TerrAscend Private Placement Oversubscribed

    TerrAscend’s recent private placement was oversubscribed due to strong investor interest. It increased the offering to about $30 million from $20 million.

    By Rajiv Nanjapla
  • uploads///cresco_
    Cannabis

    Why Beacon Securities Thinks Cresco Labs Is Cheap

    Russell Stanley of Beacon Securities is optimistic about Cresco Labs (CRLBF) in the cannabis space. He maintained the “buy” rating and target price.

    By Rajiv Nanjapla
  • uploads///cresco labs
    Cannabis

    Why Origin House’s Acquisition Is Vital for Cresco Labs

    On December 31, 2019, Origin House (OH) announced that its shareholders had approved Cresco Labs’ (CRLBF) acquisition plan.

    By Rajiv Nanjapla
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.